344510
FTase Inhibitor I
The FTase Inhibitor I controls the biological activity of FTase. This small molecule/inhibitor is primarily used for Cancer applications.
同義詞:
FTase Inhibitor I, N-[2(S)-[2(R)-Amino-3-mercaptopropylamino]-3-methylbutyl]-Phe-Met-OH, B581
登入查看組織和合約定價
全部照片(1)
About This Item
經驗公式（希爾表示法）:
C22H38N4O3S2
分子量：:
470.69
分類程式碼代碼:
12352200
推薦產品
品質等級
化驗
≥90% (HPLC)
形狀
solid
製造商／商標名
Calbiochem®
儲存條件
OK to freeze
desiccated (hygroscopic)
顏色
white
溶解度
water: 1 mg/mL
DMSO: 5 mg/mL
運輸包裝
ambient
儲存溫度
−20°C
一般說明
A potent, cell-permeable inhibitor of farnesyltransferase (FTase) that is about 37-fold more active against FTase (IC50 = 21 nM in vitro) than against geranylgeranyltransferase (GGTase; IC50 = 790 nM). Very resistant to proteolysis.
A potent, cell-permeable, selective, peptidomimetic inhibitor of farnesyltransferase (FTase) that is approximately 37-fold more active against FTase (IC50 = 21 nM in vitro) than against geranylgeranyltransferase (GGTase; IC50 = 790 nM). Very resistant to proteolysis.
生化／生理作用
Cell permeable: yes
Primary Target
FTase
FTase
Product does not compete with ATP.
Reversible: no
Target IC50: 21 nM against FTase in vitro
包裝
Packaged under inert gas
警告
Toxicity: Standard Handling (A)
外觀
Supplied as a trifluoroacetate salt.
重構
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
其他說明
Yamaguchi, M., et al. 2004. Stroke35, 1750.
Cox, A.D., et al. 1994. J. Biol. Chem.269, 19203.
Garcia, A.M., et al. 1993. J. Biol. Chem. 268, 18415.
Cox, A.D., et al. 1994. J. Biol. Chem.269, 19203.
Garcia, A.M., et al. 1993. J. Biol. Chem. 268, 18415.
法律資訊
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 1
閃點（°F）
Not applicable
閃點（°C）
Not applicable
分析證明 (COA)
輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。
Carmen M Deveau et al.
Biochemical pharmacology, 183, 114349-114349 (2020-11-28)
Serotonin neurotransmission is largely governed by the regulation of the serotonin transporter (SERT). SERT is modulated in part by cholesterol, but the role of cholesterol and lipid signaling intermediates in regulating SERT are unknown. Serotonergic neurons were treated with statins
Yusuke Marikawa et al.
Molecular human reproduction, 27(4) (2021-03-08)
Early embryos are vulnerable to environmental insults, such as medications taken by the mother. Due to increasing prevalence of hypercholesterolemia, more women of childbearing potential are taking cholesterol-lowering medications called statins. Previously, we showed that inhibition of the mevalonate pathway
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務